Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Gsk2140944
1. 1075236-89-3
2. Gsk2140944
3. Gsk-2140944
4. Gsk 2140944
5. Dvf0pr037d
6. 3h,8h-2a,5,8a-triazaacenaphthylene-3,8-dione, 2-((4-(((3,4-dihydro-2h-pyrano(2,3-c)pyridin-6-yl)methyl)amino)-1-piperidinyl)methyl)-1,2-dihydro-, (2r)-
7. (2r)-2-[(4-{[(3,4-dihydro-2h-pyrano[2,3-c]pyridin- 6-yl)methyl]amino}piperidin-1-yl)methyl]-1,2-dihydro- 3h,8h-2a,5,8a-triazaacenaphthylene-3,8-dione
8. (3~{r})-3-[[4-(3,4-dihydro-2~{h}-pyrano[2,3-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.0^{4,12}]dodeca-6,8(12),9-triene-5,11-dione
9. (3r)-3-[[4-(3,4-dihydro-2h-pyrano[2,3-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione
10. Gepotidacin [usan:inn]
11. Unii-dvf0pr037d
12. 3h,8h-2a,5,8a-triazaacenaphthylene-3,8-dione, 2-[[4-[[(3,4-dihydro-2h-pyrano[2,3-c]pyridin-6-yl)methyl]amino]-1-piperidinyl]methyl]-1,2-dihydro-, (2r)-
13. Jhn
14. Gepotidacin [inn]
15. Gepotidacin (usan/inn)
16. Gepotidacin [usan]
17. Gepotidacin [who-dd]
18. Schembl3332319
19. Chembl3317856
20. Gtpl10817
21. Dtxsid501028208
22. Bdbm50050549
23. Gsk 2140944e
24. Cs-6531
25. Db12134
26. Hy-16742
27. D10878
28. A857306
29. Q19597285
| Molecular Weight | 448.5 g/mol |
|---|---|
| Molecular Formula | C24H28N6O3 |
| XLogP3 | 0.1 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 5 |
| Exact Mass | 448.22228878 g/mol |
| Monoisotopic Mass | 448.22228878 g/mol |
| Topological Polar Surface Area | 90.4 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 893 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of uncomplicated urogenital gonorrhea
Treatment of uncomplicated urinary tract infections
Topoisomerase Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASES. (See all compounds classified as Topoisomerase Inhibitors.)
Drugs in Development
Details:
GSK 2140944 (gepotidacin) is a potential first-in-class oral antibiotic which inhibits bacterial DNA replication, with a novel mechanism of action for uncomplicated urogenital gonorrhoea.
Lead Product(s): Gepotidacin
Therapeutic Area: Infections and Infectious Diseases Brand Name: GSK 2140944
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2024
Lead Product(s) : Gepotidacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EAGLE-1 Phase III Data Show Gepotidacin As New Oral Treatment for Gonorrhoea
Details : GSK 2140944 (gepotidacin) is a potential first-in-class oral antibiotic which inhibits bacterial DNA replication, with a novel mechanism of action for uncomplicated urogenital gonorrhoea.
Product Name : GSK 2140944
Product Type : Small molecule
Upfront Cash : Not Applicable
April 17, 2024
Details:
GSK 2140944 (gepotidacin) is an investigational bactericidal antibiotic inhibiting bacterial DNA replication by a novel mechanism, evaluated for treating uncomplicated urogenital gonorrhea.
Lead Product(s): Gepotidacin
Therapeutic Area: Infections and Infectious Diseases Brand Name: GSK 2140944
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Lead Product(s) : Gepotidacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
GSK Reports Positive Results from EAGLE-1 Trial for Gepotidacin
Details : GSK 2140944 (gepotidacin) is an investigational bactericidal antibiotic inhibiting bacterial DNA replication by a novel mechanism, evaluated for treating uncomplicated urogenital gonorrhea.
Product Name : GSK 2140944
Product Type : Small molecule
Upfront Cash : Not Applicable
February 26, 2024
Details:
GSK 2140944 (gepotidacin) is an investigational bactericidal that inhibits bacterial DNA replication by a novel mechanism of action and binding site and provides well-balanced inhibition of two different Type II topoisomerase enzymes.
Lead Product(s): Gepotidacin
Therapeutic Area: Infections and Infectious Diseases Brand Name: GSK 2140944
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2023
Lead Product(s) : Gepotidacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Gepotidacin’s Positive Phase III Data Shows Potential to Be the First in A New Class of Oral Ant...
Details : GSK 2140944 (gepotidacin) is an investigational bactericidal that inhibits bacterial DNA replication by a novel mechanism of action and binding site and provides well-balanced inhibition of two different Type II topoisomerase enzymes.
Product Name : GSK 2140944
Product Type : Small molecule
Upfront Cash : Not Applicable
April 15, 2023
Details:
The EAGLE-2 and EAGLE-3 trials met primary efficacy endpoint of combined clinical and microbiological resolution following treatment at the Test-Of-Cure visit for gepotidacin (GSK 2140944) v/s nitrofurantoin in patients with uUTI and a uropathogen sensitive to nitrofurantoin.
Lead Product(s): Gepotidacin
Therapeutic Area: Infections and Infectious Diseases Brand Name: GSK 2140944
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Lead Product(s) : Gepotidacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The EAGLE-2 and EAGLE-3 trials met primary efficacy endpoint of combined clinical and microbiological resolution following treatment at the Test-Of-Cure visit for gepotidacin (GSK 2140944) v/s nitrofurantoin in patients with uUTI and a uropathogen sensit...
Product Name : GSK 2140944
Product Type : Small molecule
Upfront Cash : Not Applicable
November 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
46
PharmaCompass offers a list of Gepotidacin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Gepotidacin manufacturer or Gepotidacin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Gepotidacin manufacturer or Gepotidacin supplier.
PharmaCompass also assists you with knowing the Gepotidacin API Price utilized in the formulation of products. Gepotidacin API Price is not always fixed or binding as the Gepotidacin Price is obtained through a variety of data sources. The Gepotidacin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Gepotidacin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Gepotidacin, including repackagers and relabelers. The FDA regulates Gepotidacin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Gepotidacin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Gepotidacin supplier is an individual or a company that provides Gepotidacin active pharmaceutical ingredient (API) or Gepotidacin finished formulations upon request. The Gepotidacin suppliers may include Gepotidacin API manufacturers, exporters, distributors and traders.
Gepotidacin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Gepotidacin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Gepotidacin GMP manufacturer or Gepotidacin GMP API supplier for your needs.
A Gepotidacin CoA (Certificate of Analysis) is a formal document that attests to Gepotidacin's compliance with Gepotidacin specifications and serves as a tool for batch-level quality control.
Gepotidacin CoA mostly includes findings from lab analyses of a specific batch. For each Gepotidacin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Gepotidacin may be tested according to a variety of international standards, such as European Pharmacopoeia (Gepotidacin EP), Gepotidacin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Gepotidacin USP).
